U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications

Contributed by: Business Wire

Logo

Tags

Oncology

FDA

Health

Clinical Trials

Pharmaceutical

Biotechnology

BRUKINSA, FDA, lymphocytic leukemia

More Like This

European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia